Literature DB >> 9920186

Effects of endogenous and exogenous nitric oxide on endothelin-1 production in cultured vascular endothelial cells.

N Mitsutomi1, C Akashi, J Odagiri, Y Matsumura.   

Abstract

The effects of various spontaneous nitric oxide (NO) donors and NO synthase inhibitors on endothelin- production were examined using porcine cultured aortic endothelial cells. NO donors such as (+/-)-(E)-4-methyl-2-[(E)-hydroxyimino]-5-nitro-3-hexanamide (NOR 2), (+/-)-(E)-4-ethyl-2-[( E)-hydroxyimino]-5-nitro-3-hexanamide (NOR 3) and (+/-)-N-[(E)-4-ethyl-2-[(Z)-hydroxyimino]-5-nitro-3-hexen-1- yl]-3-pyridine carboxamide (NOR 4) suppressed effectively the release of endothelin-1 from the cells. Endothelin-1 mRNA expression was also attenuated by these compounds. Other NO donors such as 3-[2-hydroxy-1-(1-methylethyl)-2-nitrosohydrazino]-1-propanamin e (NOC 5), 2,2'-(hydroxynitrosohydrazino)bis-ethanamine (NOC 18), s-nitroso-n-acetyl-DL-penicillamine, N-morpholino sydnonimine (SIN-1) had no effects on endothelin-1 production. Endothelial intracellular cyclic guanosine monophosphate (cGMP) levels were significantly increased by all NO donors. 1H-[1,2,4]oxadiazolo[4,3-a]quinoxalin-1-one (ODQ), a selective soluble guanylyl cyclase inhibitor, had no effect on the NOR 3-induced decrease in endothelin-1 secretion, although cGMP production was abolished by ODQ. NOR 3 also inhibited endothelin-1 secretion even in the presence of 2-(4-carboxyphenyl)-4,4,5,5-tetrametylimidazole-1-oxyl 3-oxide (carboxy-PTIO), a NO scavenger. NOR 3-induced inhibitory effects on endothelin-1 secretion were abolished by preincubation of the compound in phosphate-buffered saline (37 degrees C, 4 h), a procedure by which about 98% of the parent compound's ability to release NO was lost. NO synthase inhibitors such as N(G)-nitro-L-arginine, N(G)-monomethyl-L-arginine and N(G)-nitro-L-arginine methyl ester (L-NAME) enhanced prepro endothelin-1 mRNA expression and significantly increased endothelin-1 release from endothelial cells. Endothelin-1 secretion was also increased effectively by carboxy-PTIO or ODQ. When the cells were exposed to L-NAME with carboxy-PTIO or ODQ, no significant further increase in endothelin-1 release was observed. These results suggest that endogenous NO inhibits endothelin-1 production through guanylyl cyclase/cGMP-dependent mechanisms. In contrast, it seems unlikely that exogenous NO has an inhibitory effect on endothelin-1 production in endothelial cells. NOR compounds inhibit endothelin-1 production perhaps through NO/cGMP-independent mechanisms, i.e., through an unknown effect of the parent compound itself.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 9920186     DOI: 10.1016/s0014-2999(98)00806-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  5 in total

1.  Autonomic contribution to endothelin-1 increase during laboratory anger-recall stress in patients with coronary artery disease.

Authors:  Matthew M Burg; Aaron Soufer; Rachel Lampert; Dorothea Collins; Robert Soufer
Journal:  Mol Med       Date:  2011-01-19       Impact factor: 6.354

Review 2.  Endothelial and Smooth Muscle Cell Interactions in the Pathobiology of Pulmonary Hypertension.

Authors:  Yuansheng Gao; Tianji Chen; J Usha Raj
Journal:  Am J Respir Cell Mol Biol       Date:  2016-04       Impact factor: 6.914

3.  Linking regulation of nitric oxide to endothelin-1: The Yin and Yang of vascular tone in the atherosclerotic plaque.

Authors:  Rajat M Gupta; Peter Libby; Matthias Barton
Journal:  Atherosclerosis       Date:  2019-11-14       Impact factor: 6.847

4.  Downregulation of endothelial nitric oxide synthase (eNOS) and endothelin-1 (ET-1) in a co-culture system with human stimulated X-linked CGD neutrophils.

Authors:  Akari Nakamura-Utsunomiya; Miyuki Tsumura; Satoshi Okada; Hiroshi Kawaguchi; Masao Kobayashi
Journal:  PLoS One       Date:  2020-04-06       Impact factor: 3.240

Review 5.  Pharmacological hypothesis: Nitric oxide-induced inhibition of ADAM-17 activity as well as vesicle release can in turn prevent the production of soluble endothelin-converting enzyme.

Authors:  Sanjaya Kuruppu; Niwanthi W Rajapakse; Helena C Parkington; Ian Smith
Journal:  Pharmacol Res Perspect       Date:  2017-10
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.